Putting an end to DEND
A severe neonatal-onset epilepsy is treatable—if recognized early
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
This issue contains the first report in the neurologic literature of a potentially catastrophic infantile neurodevelopmental syndrome that, though rare, may turn out to be highly treatable.1 Shimomura et al. describe a male child, first encountered at 3.5 years of age, with a history of neonatal-onset diabetes mellitus and neonatal seizures that had progressed to infantile spasms, severe developmental delay, and medically refractory epilepsy. Attentive care (round-the-clock hourly glucose monitoring; insulin infusion by subcutaneous pump; multiple antiepileptic drug trials) had proven ineffective. Remarkably, the patient showed a dramatic response to treatment with oral glibenclamide, a sulfonylurea drug most often given to adult patients with noninsulin dependent diabetes. Glucose control improved, allowing discontinuation of insulin. In addition, electrographic signs of seizures and encephalopathy diminished, and neurodevelopmental progress resumed. Evidence from this case and others reported elsewhere2 suggests that early recognition and sulfonylurea treatment is essential for this treatment to be effective.
Why did Shimomura et al. choose glibenclamide, and why did an oral agent work after insulin had failed? The authors recognized that their patient had delay, epilepsy, and neonatal …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.